Top

Published in:

01-09-2015 | Research Article

Interaction with CCNH/CDK7 facilitates CtBP2 promoting esophageal squamous cell carcinoma (ESCC) metastasis via upregulating epithelial-mesenchymal transition (EMT) progression

Authors: Jianguo Zhang, Junya Zhu, Lei Yang, Chengqi Guan, Runzhou Ni, Yuchan Wang, Lili Ji, Ye Tian

Published in: Tumor Biology | Issue 9/2015

Abstract

CtBP2, as a transcriptional corepressor of epithelial-specific genes, has been reported to promote tumor due to upregulating epithelial-mesenchymal transition (EMT) in cancer cells. CtBP2 was also demonstrated to contribute to the proliferation of esophageal squamous cell carcinoma (ESCC) cells through a negative transcriptional regulation of p16^INK4A. In this study, for the first time, we reported that CtBP2 expression, along with CCNH/CDK7, was higher in ESCC tissues with lymph node metastases than in those without lymph node metastases. Moreover, both CtBP2 and CCNH/CDK7 were positively correlated with E-cadherin, tumor grade, and tumor metastasis. However, the concrete mechanism of CtBP2’s role in enhancing ESCC migration remains incompletely understood. We confirmed that CCNH/CDK7 could directly interact with CtBP2 in ESCC cells in vivo and in vitro. Furthermore, our data demonstrate for the first time that CtBP2 enhanced the migration of ESCC cells in a CCNH/CDK7-dependent manner. Our results indicated that CCNH/CDK7-CtBP2 axis may augment ESCC cell migration, and targeting the interaction of both may provide a novel therapeutic target of ESCC.

Li X, Suo J, Shao S, Xue L, Chen W, Dong L, et al. Overexpression of OLC1 promotes tumorigenesis of human esophageal squamous cell carcinoma. PLoS One. 2014;9(3):e90958. doi:10.1371/journal.pone.0090958.CrossRefPubMedPubMedCentral

Guan C, Shi H, Wang H, Zhang J, Ni W, Chen B, et al. CtBP2 contributes to malignant development of human esophageal squamous cell carcinoma by regulation of p16INK4A. J Cell Biochem. 2013;114(6):1343–54. doi:10.1002/jcb.24475.CrossRefPubMed

Zhang L, Wu YD, Li P, Tu J, Niu YL, Xu CM, et al. Effects of cyclooxygenase-2 on human esophageal squamous cell carcinoma. World J Gastroenterol: WJG. 2011;17(41):4572–80. doi:10.3748/wjg.v17.i41.4572.CrossRefPubMedPubMedCentral

Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349(23):2241–52. doi:10.1056/NEJMra035010.CrossRefPubMed

Li M, Yang X, Shi H, Ren H, Chen X, Zhang S, et al. Downregulated expression of the cyclase-associated protein 1 (CAP1) reduces migration in esophageal squamous cell carcinoma. Jpn J Clin Oncol. 2013;43(9):856–64. doi:10.1093/jjco/hyt093.CrossRefPubMed

Shagieva GS, Domnina LV, Chipysheva TA, Ermilova VD, Chaponnier C, Dugina VB. Actin isoforms and reorganization of adhesion junctions in epithelial-to-mesenchymal transition of cervical carcinoma cells. Biochem Biokhim. 2012;77(11):1266–76. doi:10.1134/S0006297912110053.CrossRef

Shi J, Wang DM, Wang CM, Hu Y, Liu AH, Zhang YL, et al. Insulin receptor substrate-1 suppresses transforming growth factor-beta1-mediated epithelial-mesenchymal transition. Cancer Res. 2009;69(18):7180–7. doi:10.1158/0008-5472.CAN-08-4470.CrossRefPubMed

Wang Y, Liu F, Mao F, Hang Q, Huang X, He S, et al. Interaction with cyclin H/cyclin-dependent kinase 7 (CCNH/CDK7) stabilizes C-terminal binding protein 2 (CtBP2) and promotes cancer cell migration. J Biol Chem. 2013;288(13):9028–34. doi:10.1074/jbc.M112.432005.CrossRefPubMedPubMedCentral

Prindull G, Zipori D. Environmental guidance of normal and tumor cell plasticity: epithelial mesenchymal transitions as a paradigm. Blood. 2004;103(8):2892–9. doi:10.1182/blood-2003-08-2807.CrossRefPubMed

10.

Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol. 2006;172(7):973–81. doi:10.1083/jcb.200601018.CrossRefPubMedPubMedCentral

11.

Voulgari A, Pintzas A. Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta. 2009;1796(2):75–90. doi:10.1016/j.bbcan.2009.03.002.PubMed

12.

Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7(2):131–42. doi:10.1038/nrm1835.CrossRefPubMed

13.

Tse JC, Kalluri R. Mechanisms of metastasis: epithelial-to-mesenchymal transition and contribution of tumor microenvironment. J Cell Biochem. 2007;101(4):816–29. doi:10.1002/jcb.21215.CrossRefPubMed

14.

Hugo H, Ackland ML, Blick T, Lawrence MG, Clements JA, Williams ED, et al. Epithelial–mesenchymal and mesenchymal–epithelial transitions in carcinoma progression. J Cell Physiol. 2007;213(2):374–83. doi:10.1002/jcp.21223.CrossRefPubMed

15.

Boyd JM, Subramanian T, Schaeper U, La Regina M, Bayley S, Chinnadurai G. A region in the C-terminus of adenovirus 2/5 E1a protein is required for association with a cellular phosphoprotein and important for the negative modulation of T24-ras mediated transformation, tumorigenesis and metastasis. EMBO J. 1993;12(2):469–78.PubMedPubMedCentral

16.

Schaeper U, Boyd JM, Verma S, Uhlmann E, Subramanian T, Chinnadurai G. Molecular cloning and characterization of a cellular phosphoprotein that interacts with a conserved C-terminal domain of adenovirus E1A involved in negative modulation of oncogenic transformation. Proc Natl Acad Sci U S A. 1995;92(23):10467–71.CrossRefPubMedPubMedCentral

17.

Zhang Q, Wang SY, Nottke AC, Rocheleau JV, Piston DW, Goodman RH. Redox sensor CtBP mediates hypoxia-induced tumor cell migration. Proc Natl Acad Sci U S A. 2006;103(24):9029–33. doi:10.1073/pnas.0603269103.CrossRefPubMedPubMedCentral

18.

Grooteclaes ML, Frisch SM. Evidence for a function of CtBP in epithelial gene regulation and anoikis. Oncogene. 2000;19(33):3823–8. doi:10.1038/sj.onc.1203721.CrossRefPubMed

19.

Tang L, Yang J, Ng SK, Rodriguez N, Choi PW, Vitonis A, et al. Autoantibody profiling to identify biomarkers of key pathogenic pathways in mucinous ovarian cancer. Eur J Cancer. 2010;46(1):170–9. doi:10.1016/j.ejca.2009.10.003.CrossRefPubMedPubMedCentral

20.

Barroilhet L, Yang J, Hasselblatt K, Paranal RM, Ng SK, Rauh-Hain JA, et al. C-terminal binding protein-2 regulates response of epithelial ovarian cancer cells to histone deacetylase inhibitors. Oncogene. 2013;32(33):3896–903. doi:10.1038/onc.2012.380.CrossRefPubMed

21.

Birts CN, Harding R, Soosaipillai G, Halder T, Azim-Araghi A, Darley M, et al. Expression of CtBP family protein isoforms in breast cancer and their role in chemoresistance. Biol Cell Under Auspices Eur Cell Biol Organ. 2010;103(1):1–19. doi:10.1042/BC20100067.CrossRef

22.

Fujii W, Nishimura T, Kano K, Sugiura K, Naito K. CDK7 and CCNH are components of CDK-activating kinase and are required for meiotic progression of pig oocytes. Biol Reprod. 2011;85(6):1124–32. doi:10.1095/biolreprod.111.091801.CrossRefPubMed

23.

Bartkova J, Zemanova M, Bartek J. Expression of CDK7/CAK in normal and tumor cells of diverse histogenesis, cell-cycle position and differentiation. Int J Cancer. 1996;66(6):732–7. doi:10.1002/(SICI)1097-0215(19960611)66:6<732::AID-IJC4>3.0.CO;2-0.CrossRefPubMed

24.

Fei M, Lu M, Wang Y, Zhao Y, He S, Gao S, et al. Arsenic trioxide-induced growth arrest of human hepatocellular carcinoma cells involving FOXO3a expression and localization. Med Oncol. 2009;26(2):178–85. doi:10.1007/s12032-008-9105-8.CrossRefPubMed

25.

Mouriaux F, Casagrande F, Pillaire MJ, Manenti S, Malecaze F, Darbon JM. Differential expression of G1 cyclins and cyclin-dependent kinase inhibitors in normal and transformed melanocytes. Invest Ophthalmol Vis Sci. 1998;39(6):876–84.PubMed

26.

Collins CS, Hong J, Sapinoso L, Zhou Y, Liu Z, Micklash K, et al. A small interfering RNA screen for modulators of tumor cell motility identifies MAP4K4 as a promigratory kinase. Proc Natl Acad Sci U S A. 2006;103(10):3775–80. doi:10.1073/pnas.0600040103.CrossRefPubMedPubMedCentral

27.

Sobin LH, Fleming ID. TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer. 1997;80(9):1803–4.CrossRefPubMed

28.

Wang Y, Yang S, Ni Q, He S, Zhao Y, Yuan Q, et al. Overexpression of forkhead box J2 can decrease the migration of breast cancer cells. J Cell Biochem. 2012;113(8):2729–37. doi:10.1002/jcb.24146.CrossRefPubMed

29.

Scheel C, Weinberg RA. Phenotypic plasticity and epithelial-mesenchymal transitions in cancer and normal stem cells? Int J Cancer. 2011;129(10):2310–4. doi:10.1002/ijc.26311.CrossRefPubMedPubMedCentral

30.

Zhang J, Yang X, Wang Y, Shi H, Guan C, Yao L, et al. Low expression of cyclinH and cyclin-dependent kinase 7 can decrease the proliferation of human esophageal squamous cell carcinoma. Dig Dis Sci. 2013;58(7):2028–37. doi:10.1007/s10620-013-2597-x.CrossRefPubMed

31.

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi:10.3322/caac.20107.CrossRefPubMed

32.

Eccles SA, Welch DR. Metastasis: recent discoveries and novel treatment strategies. Lancet. 2007;369(9574):1742–57. doi:10.1016/S0140-6736(07)60781-8.CrossRefPubMedPubMedCentral

33.

Chuangui C, Peng T, Zhentao Y. The expression of high mobility group box 1 is associated with lymph node metastasis and poor prognosis in esophageal squamous cell carcinoma. Pathol Oncol Res: POR. 2012;18(4):1021–7. doi:10.1007/s12253-012-9539-3.CrossRefPubMed

34.

Wang Y, Zhou S, Yang X, Shi H, Li M, Xue Q, et al. Low expression of cyclic AMP response element modulator-1 can increase the migration and invasion of esophageal squamous cell carcinoma. Tumour Biol J Int Soc Oncodev Biol Med. 2013;34(6):3649–57. doi:10.1007/s13277-013-0946-1.CrossRef

35.

Paliwal S, Ho N, Parker D, Grossman SR. CtBP2 promotes human cancer cell migration by transcriptional activation of Tiam1. Genes Cancer. 2012;3(7–8):481–90. doi:10.1177/1947601912463695.PubMedPubMedCentral

36.

Paliwal S, Kovi RC, Nath B, Chen YW, Lewis BC, Grossman SR. The alternative reading frame tumor suppressor antagonizes hypoxia-induced cancer cell migration via interaction with the COOH-terminal binding protein corepressor. Cancer Res. 2007;67(19):9322–9. doi:10.1158/0008-5472.CAN-07-1743.CrossRefPubMed

Title: Interaction with CCNH/CDK7 facilitates CtBP2 promoting esophageal squamous cell carcinoma (ESCC) metastasis via upregulating epithelial-mesenchymal transition (EMT) progression
Authors: Jianguo Zhang
Junya Zhu
Lei Yang
Chengqi Guan
Runzhou Ni
Yuchan Wang
Lili Ji
Ye Tian
Publication date: 01-09-2015
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 9/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-3354-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2015

Retraction Note to: Relationship of serum MMP-7 levels for colorectal cancer: a meta-analysis

Lifetime effectiveness of mifamurtide addition to chemotherapy in nonmetastatic and metastatic osteosarcoma: a Markov process model analysis

Decreased expression of RPS15A suppresses proliferation of lung cancer cells

Retraction Note to: Effect of NS-398, a cyclooxygenase-2 selective inhibitor, on the cytotoxicity of cytotoxic T lymphocytes to ovarian carcinoma cells

Effect of thymidylate synthase gene polymorphism on the response to chemotherapy and clinical outcome of non-small cell lung cancer patients

JARID1B modulates lung cancer cell proliferation and invasion by regulating p53 expression

Keynote webinar | Spotlight on antibody–drug conjugates in cancer